<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744182</url>
  </required_header>
  <id_info>
    <org_study_id>HM-TRIA-102</org_study_id>
    <nct_id>NCT03744182</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Doses of HM15211 in Obese Subjects With NAFLD and in Subjects With NASH</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211 in Obese Subjects With NAFLD and in Subjects With NASH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD and in subjects
      with NASH
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">September 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical lab abnormalities</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of clinical lab abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence and severity of clinical findings on physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in 12-lead ECG</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>NAFLD</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>HM15211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM15211</intervention_name>
    <description>A sterile solution of HM15211 contained in pre-filled syringes</description>
    <arm_group_label>HM15211</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of HM15211</intervention_name>
    <description>A sterile, matching solution in pre-filled syringes</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index ≥ 30 kg/m2

          -  Waist circumference ≤ 57 inches

          -  Fasting Plasma Glucose &lt; 7 mmol/L (126 mg/dL)

          -  HbA1c &lt; 6.5%

          -  Controlled Attenuation Parameter ≥ 300 dB/m by FibroScan

          -  Liver fat by MRI-PDFF ≥ 10%.

        Exclusion Criteria:

          -  A history of or active chronic liver disease due to alcohol, auto-immune, HIV, HBV or
             active HCV-infection or NASH disease

          -  Any history of clinically significant chronic liver disease including esophageal
             varices, ascites, encephalopathy or any hospitalization for treatment of chronic liver
             disease; or Model for End Stage Liver Disease (MELD) ≥ 10

          -  Previous surgical treatment for obesity

          -  Uncontrolled hypertension

          -  Any weight control treatment

          -  History or current diagnosis of acute or chronic pancreatitis or factors for
             pancreatitis

          -  History of major depression, anxiety, suicidal behavior or attempts, or other
             psychiatric disorder requiring medical treatment

          -  History or current diagnosis of heart disease

          -  Presence of clinically significant ECG findings

          -  History of renal disease or abnormal kidney function tests

          -  History of alcohol or illicit drug abuse

          -  Daily heavy use of cigarettes or any tobacco product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jahoon Kang, Executive Director</last_name>
    <phone>+82 2 410 9041</phone>
    <email>jhkang@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ProSciento Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Hompesch, CEO</last_name>
    </contact>
    <investigator>
      <last_name>Linda Morrow, VP, CMO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

